Liquidia (LQDA) Cash from Investing Activities (2020 - 2026)

Liquidia's (LQDA) quarterly Cash from Investing Activities came in at -$2.8 million in Q1 2026, down 757.58% year-on-year from $430368.7 in Q1 2025, and up 29.92% quarter-over-quarter from -$4.0 million in Q4 2025.

Liquidia (LQDA) Cash from Investing Activities (2020 - 2026) Analysis & Trends

Liquidia's Cash from Investing Activities history runs 7 years deep, the most recent figure standing at -$2.8 million for Q1 2026.

  • On a quarterly basis, Cash from Investing Activities fell 757.58% year-over-year to -$2.8 million in Q1 2026; TTM through Mar 2026 was -$8.8 million, a 8.46% decrease from a year earlier, with the FY2025 full-year figure at -$6.3 million, up 24.94% from the prior year.
  • Cash from Investing Activities rose to -$2.8 million in Q1 2026 per LQDA's latest filing, from -$4.0 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at -$2000.0 in Q2 2022 and bottomed at -$10.5 million in Q3 2023.
  • The 5-year median for Cash from Investing Activities is -$767500.0 (2024), against an average of -$1.8 million.
  • Across the five-year window, Cash from Investing Activities surged 94.29% in 2022 and tumbled 12050.0% in 2023, its largest moves.
  • Year by year, Cash from Investing Activities stood at -$491000.0 in 2022, then surged by 58.04% to -$206000.0 in 2023, then sank by 2220.39% to -$4.8 million in 2024, then increased by 15.52% to -$4.0 million in 2025, then climbed by 29.92% to -$2.8 million in 2026.
  • Per Business Quant, the three latest LQDA Cash from Investing Activities figures stand at -$2.8 million (Q1 2026), -$4.0 million (Q4 2025), and -$911000.0 (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Investing Activities (Qtr)
1 Haleon 89.28 Bn 87.42 Bn - -
2 Teva Pharmaceutical Industries 35.97 Bn 32.23 Bn 1.97 Bn 229.00 Mn
3 Zoetis 32.42 Bn 30.48 Bn 1.62 Bn -87.00 Mn
4 Takeda Pharmaceutical 27.48 Bn 23.42 Bn 4.39 Bn -369.95 Mn
5 United Therapeutics 22.89 Bn 20.73 Bn 648.10 Mn 743.70 Mn
6 RedHill Biopharma 22.11 Bn 22.11 Bn - -
7 Viatris 20.44 Bn 18.64 Bn 1.16 Bn 277.40 Mn
8 Neurocrine Biosciences 17.76 Bn 16.44 Bn 800.70 Mn -506.20 Mn
9 Elanco Animal Health 12.62 Bn 12.19 Bn 785.00 Mn -60.00 Mn
10 Liquidia 7.47 Bn 7.25 Bn 121.79 Mn -2.83 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -2.83 Mn
Mar 31, 2026 -2.83 Mn
Dec 31, 2025 -4.04 Mn
Dec 31, 2025 -4.04 Mn
Sep 30, 2025 -911,000.00
Sep 30, 2025 -911,000.00
Jun 30, 2025 -1.06 Mn
Jun 30, 2025 -1.06 Mn
Mar 31, 2025 -330,000.00
Mar 31, 2025 -330,000.00
Dec 31, 2024 -4.78 Mn
Dec 31, 2024 -4.78 Mn
Sep 30, 2024 -1.75 Mn
Sep 30, 2024 -1.75 Mn
Jun 30, 2024 -1.29 Mn
Jun 30, 2024 -1.29 Mn
Mar 31, 2024 -624,000.00
Mar 31, 2024 -624,000.00
Dec 31, 2023 -206,000.00
Dec 31, 2023 -206,000.00